LXRX - Lexicon Pharmaceuticals, Inc.
| Previous Close | 3.8000 |
| Open | 3.8100 |
| Bid | 3.4700 x 4000 |
| Ask | 3.5000 x 2200 |
| Day's Range | 3.3200 - 3.8500 |
| 52 Week Range | 1.1300 - 11.5100 |
| Volume | 5,358,948 |
| Avg. Volume | 2,030,343 |
| Market Cap | 366.638M |
| Beta (3Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8390 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Zacks
Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%
Lexicon (LXRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Benzinga
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...
- American City Business Journals
Woodlands-based pharma co. to receive $260M in drug dispute settlement
In addition to a $260 million payout, the drug dispute settlement returns worldwide development and commercialization rights to Houston-area firm.
- Zacks
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
- Benzinga
The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 10) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- Reuters
Sanofi to pay Lexicon $260 mln for terminated partnership
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership. The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
- GlobeNewswire
Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting
THE WOODLANDS, Texas, Sept. 10, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at.
- GlobeNewswire
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
Lexicon Pharmaceuticals, Inc. (LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM (sotagliflozin) and the settlement of its related disputes with Sanofi, each effective September 9, 2019. In connection with the termination, Lexicon will regain all rights to Zynquista and assume full responsibility for the worldwide development and commercialization of Zynquista in both type 1 and type 2 diabetes.
- Simply Wall St.
Market Sentiment Around Loss-Making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on...
- Motley Fool
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
- GlobeNewswire
Lexicon Pharmaceuticals To Present At Upcoming Investor Conference
THE WOODLANDS, Texas, Aug. 30, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and.
- Thomson Reuters StreetEvents
Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT
Q2 2019 Lexicon Pharmaceuticals Inc Earnings Call
- GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares
President and CEO of Lexicon Pharmaceuticals Inc (30-Year Financial, Insider Trades) Lonnel Coats (insider trades) bought 40,000 shares of LXRX on 08/19/2019 at an average price of $1.35 a share. Continue reading...
- GlobeNewswire
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
THE WOODLANDS, Texas, Aug. 09, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and.
- GlobeNewswire
Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS,.
- Zacks
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
- Zacks
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
THE WOODLANDS, Texas, July 31, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.
- GlobeNewswire
Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019
Lexicon Pharmaceuticals, Inc. (LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2019 on Wednesday, July 31, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
- Motley Fool
Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today
Earnings and other woes weighed on these stocks.
- Motley Fool
Here's Why Lexicon Pharmaceuticals Is Collapsing Today
Sanofi is walking away from an important collaboration, leaving shareholders wondering what's next.
- MarketWatch
Lexicon's stock loses more than half its value after Sanofi's notice to end alliance
Shares of Lexicon Pharmaceuticals Inc. lost more than half their value (down 53.4%) toward a record low in active premarket trading Monday, after the drug maker said Sanofi wanted to end the alliance around its diabetes treatment Zynquista. The stock was on track to open 38% below its Jan. 29, 2019 record low close of $4.36, with trading volume of 583,000 shares already more than the full-day average of 349,800 shares. Lexicon said it considers Sanofi's notice to be invalid and "in breach of contract." Sanofi's decision to terminate the alliance late Friday came as Lexicon provided preliminary data from a phase 3 trial of Zynquista; Lexicon said it has not yet received the underlying data and expects to conduct its own review and validation of the statistical analysis. Analyst Stephen Wiley at Stifel Nicolaus downgraded Lexicon's stock to hold from buy and cut his price target to $4 from $10, saying Sanofi's notice creates more uncertainty for Lexicon's story, which "already lacked meaningful visibility." The stock has lost 14% year to date through Friday, while the S&P 500 has gained 21%.
- Reuters
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies. In a separate statement, Lexicon said it had not yet received the underlying data from the studies and that it expects to conduct its own review. "While we are disappointed in the position taken by Sanofi, we are confident in the strength of the data we have seen thus far in the type 2 diabetes program," Lexicon Chief Executive Officer Lonnel Coats said.
- Reuters
UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes. Shares of Lexicon fell nearly 40% in extended trading. Sanofi said the termination of the partnership comes after the results of three late-stage studies of the oral drug, Zynquista, which is being jointly developed by the two companies.
- GlobeNewswire
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
Lexicon Pharmaceuticals, Inc. (LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical program. In SOTA-MET, Zynquista 400 mg demonstrated a statistically significant reduction in blood sugar control (A1C) compared to placebo at 26 weeks in patients on metformin. In SOTA-CKD3, Zynquista 400 mg showed a statistically significant reduction in A1C in the entire population of patients with moderate (stage 3) chronic kidney disease (CKD) and in the subpopulation of patients with a glomerular filtration rate of 45-
